A SETD2 inhibitor with Fast Track Status for hematological malignancies, a CNS-penetrating, ATP-competitive LRRK2 inhibitor for Parkinson’s disease, and an oral nonsteroidal mineralocorticoid receptor antagonist are some examples of this month's MOTM. In the slide deck, you'll find a small molecule that modulates a protein that has only been targeted with antibodies so far and a drug that takes advantage of the glutamate NMDA receptor hypofunction hypothesis. Check out the ten molecule minireviews in the slide deck, which covers:

• Where are all of the Molecules of the Month in clinical development?

• What's known about differentiation from previous molecules?

• Where did the starting points come from?

• Industry context, mechanism of action details, and more…

Thanks to reviewers Bryan McKibben, PhD and Chris Gampe, PhD for their nominations and commentary this month.